MarketCap
Facebook
X
TelegramQuarterly report 2025-Q4
added 02-11-2026
Enanta Pharmaceuticals Depreciation & Amortization 2011-2026 | ENTA
Annual Depreciation & Amortization Enanta Pharmaceuticals
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 4.59 M | 2.34 M | 2.37 M | 2.97 M | 3.33 M | 3.64 M | 3.26 M | 2.52 M | 2.14 M | 1.66 M | 639 K | 352 K | 221 K | 172 K | 499 K |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 4.59 M | 172 K | 2.05 M |
Quarterly Depreciation & Amortization Enanta Pharmaceuticals
| 2025-Q4 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1.23 M | - | - | 889 K | - | - | - | 642 K | - | - | - | 511 K | 2.32 M | - | - | 780 K | 2.53 M | 1.7 M | - | 871 K | 2.74 M | 1.82 M | 871 K | 904 K | 2.37 M | 1.48 M | 904 K | 680 K | 1.86 M | 1.2 M | 680 K | 587 K | 1.57 M | 1.02 M | 587 K | 493 K | 1.21 M | 772 K | 493 K | 339 K | 435 K | 270 K | 339 K | 129 K | 242 K | 154 K | 129 K | 75 K | 148 K | 87 K | 75 K | 39 K | 133 K | 98 K | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 2.74 M | 39 K | 846 K |
Depreciation & Amortization of other stocks in the Biotechnology industry
| Issuer | Depreciation & Amortization | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Aquestive Therapeutics
AQST
|
548 K | $ 4.16 | 1.46 % | $ 445 M |  USA |
 |
AgeX Therapeutics
AGE
|
100 K | - | -10.17 % | $ 12.2 K | USA |
 |
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
|
24.9 M | $ 9.77 | 1.82 % | $ 632 M | USA |
 |
I-Mab
IMAB
|
23.9 M | - | - | $ 866 M |  China |
 |
Akero Therapeutics
AKRO
|
18 K | - | - | $ 3.67 B | USA |
 |
AlloVir
ALVR
|
13 K | - | 4.14 % | $ 49.1 M | USA |
 |
ACADIA Pharmaceuticals
ACAD
|
920 K | $ 22.15 | -1.36 % | $ 3.67 B | USA |
 |
Athira Pharma
ATHA
|
972 K | - | - | $ 269 M | USA |
 |
Applied Molecular Transport
AMTI
|
3.13 M | - | - | $ 10.1 M | USA |
 |
Ayala Pharmaceuticals
AYLA
|
162 K | - | - | $ 7.46 M |  Israel |
 |
Cerus Corporation
CERS
|
1.43 M | $ 2.79 | 37.44 % | $ 532 M | USA |
 |
Atreca
BCEL
|
5.46 M | - | -11.76 % | $ 5.79 M | USA |
 |
Berkeley Lights
BLI
|
9 M | - | -7.31 % | $ 87 M | USA |
 |
Calithera Biosciences
CALA
|
300 K | - | -10.95 % | $ 876 K | USA |
 |
Advaxis
ADXS
|
369 K | - | -9.65 % | $ 45.9 M | USA |
 |
CymaBay Therapeutics
CBAY
|
681 K | - | - | $ 3.45 B | USA |
 |
ChemoCentryx
CCXI
|
3.14 M | - | - | $ 3.74 B | USA |
 |
Caladrius Biosciences
CLBS
|
174 K | - | -16.75 % | $ 25.8 M | USA |
 |
Checkmate Pharmaceuticals
CMPI
|
66 K | - | - | $ 231 M | USA |
 |
Cardiff Oncology
CRDF
|
364 K | $ 1.72 | -0.87 % | $ 115 M | USA |
 |
Aeterna Zentaris
AEZS
|
58 K | - | 5.93 % | $ 314 M |  Canada |
 |
Brainstorm Cell Therapeutics
BCLI
|
199 K | - | -2.5 % | $ 5.88 M | USA |
 |
Aeglea BioTherapeutics
AGLE
|
744 K | - | - | $ 1.01 B | USA |
 |
Applied Genetic Technologies Corporation
AGTC
|
1.51 M | - | - | $ 26.5 M | USA |
 |
Deciphera Pharmaceuticals
DCPH
|
2.1 M | - | - | $ 2.18 B | USA |
 |
AIkido Pharma
AIKI
|
105 K | - | 1.93 % | $ 17.4 M | USA |
 |
Dynavax Technologies Corporation
DVAX
|
4.63 M | - | - | $ 2.02 B | USA |
 |
Akouos
AKUS
|
2.49 M | - | 0.23 % | $ 488 M | USA |
 |
Allakos
ALLK
|
6.14 M | - | - | $ 28.6 M | USA |
 |
Can-Fite BioPharma Ltd.
CANF
|
24 K | $ 2.93 | -8.15 % | $ 4.82 M | Israel |
 |
Eiger BioPharmaceuticals
EIGR
|
275 K | - | -9.21 % | $ 2.55 M | USA |
 |
Editas Medicine
EDIT
|
5.28 M | $ 2.9 | -3.48 % | $ 257 M | USA |
 |
Eloxx Pharmaceuticals
ELOX
|
77 K | - | -5.68 % | $ 8.28 M | USA |
 |
Edesa Biotech
EDSA
|
186 K | $ 17.81 | -2.57 % | $ 56.9 M | USA |
 |
Ampio Pharmaceuticals
AMPE
|
122 K | - | -11.43 % | $ 502 K | USA |
 |
Aptose Biosciences
APTO
|
22 K | - | -45.71 % | $ 1.2 M | Canada |
 |
Aptinyx
APTX
|
122 K | - | -39.0 % | $ 4.57 M | USA |